Technical Analysis for EXEL - Exelixis, Inc.

Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Chemistry Biotechnology Cancer Treatment Of Cancer Cyclopropanes Sanofi Tyrosine Kinase Inhibitors Protein Kinase Inhibitor Genentech Small Molecule Therapies Metastatic Castration Resistant Prostate Cancer